# AXIFI — The Longevity Intelligence Platform

> AI-powered longevity clinical intelligence with 1203 AXIFI-published library documents and 211 blog articles.
> Last Updated: 2026-10-08

## Locked Platform Stats

- AXIFI published library: 1203 documents (approved + public)
- Connected to 36M+ PubMed-indexed citations (external literature connectivity — not AXIFI-hosted document count)
- 50+ AI Agents
- 200 Biomarkers Interpreted
- 12 Wearable Devices
- Drug & compound interaction checks
- 1026+ Clinical Protocols (physician platform capability — not public /library browse)

## About

AXIFI is the Longevity Intelligence Platform for clinical research and practice. It provides a published research library, treatment protocols for verified physicians, and an AI research assistant connected to large external literature sources.

The platform covers:
- Peptide therapeutics (BPC-157, GHK-Cu, Thymosin, DSIP, and more)
- Exosome therapy and cellular communication
- Hormone optimization and metabolic balance
- PRP (Platelet-Rich Plasma) therapy
- Integrative clinical research approaches

## Key Pages

- [Homepage](https://www.axifi.ai/): Overview of the research platform
- [Research Library](https://www.axifi.ai/library): Searchable AXIFI-published documents
- [AI Research Assistant](https://www.axifi.ai/chat): Chat with AXIFI AI for instant research answers
- [Search](https://www.axifi.ai/search): Search across all documents and therapies
- [Therapies](https://www.axifi.ai/therapies): Therapy categories and protocols

## Therapy Categories

- [Metabolic & GLP-1 Therapies](https://www.axifi.ai/metabolic-glp1): GLP-1 receptor agonists, dual and triple agonists, oral GLP-1 formulations, amylin analogs, metabolic peptides, and prescription weight management agents targeting insulin sensitivity, appetite regulation, body composition, and metabolic longevity.
- [Longevity & Anti-Aging](https://www.axifi.ai/longevity-anti-aging): Senolytics, mTOR inhibitors, epigenetic compounds, telomere biology agents, caloric restriction mimetics, polyamines, and longevity vitamins that target the hallmarks of aging to extend healthspan and biological resilience.
- [Peptide Blends & Stacks](https://www.axifi.ai/peptide-blends-stacks): Purpose-built multi-peptide formulations and curated stacking protocols combining synergistic compounds for healing, performance, longevity, cognitive enhancement, and aesthetic outcomes.
- [Supplements & Nutraceuticals](https://www.axifi.ai/supplements): Evidence-graded vitamins, minerals, adaptogens, amino acids, polyphenols, anti-inflammatory compounds, omega fatty acids, and methylation support nutrients that form the nutritional foundation of longevity and precision health.
- [PRP & PRF Therapies](https://www.axifi.ai/prp-prf): Platelet-rich plasma and platelet-rich fibrin protocols for orthopedic injury repair, aesthetic skin rejuvenation, hair restoration, sexual health enhancement, and advanced PRF membrane applications.
- [Exosome Therapies](https://www.axifi.ai/exosome-therapies): Extracellular vesicle-based therapies delivered systemically via IV, orthopedic injection, aesthetic application, hair follicle targeting, sexual health regeneration, and intranasal routes for CNS access.
- [Growth Hormone Secretagogues](https://www.axifi.ai/growth-hormone-secretagogues): GHRH analogs, GHRP-class peptides, oral GH secretagogues, and recombinant growth hormone compounds that stimulate endogenous GH release, supporting body composition, recovery, sleep quality, and anabolic signaling.
- [Stem Cell Therapies](https://www.axifi.ai/stem-cell-therapies): Autologous and allogeneic stem cell protocols, perinatal tissue therapies, and combined cellular approaches targeting tissue regeneration, immune modulation, and systemic anti-aging through cellular replenishment.
- [Cognitive Enhancement & Nootropics](https://www.axifi.ai/cognitive-nootropics): Cholinergics, racetams, peptide nootropics, cognitive adaptogens, wakefulness agents, neuroprotective compounds, and medicinal mushroom extracts that enhance memory, focus, processing speed, and long-term brain resilience.
- [Sports Medicine & Performance](https://www.axifi.ai/sports-medicine-performance): Injury recovery peptides, muscle preservation agents, SARMs, endurance compounds, ergogenics, sports IV protocols, and sleep-recovery optimization for athletes and high-performance individuals.
- [Combination Protocols](https://www.axifi.ai/combination-protocols): Curated multi-therapy protocol stacks combining peptides, hormones, regenerative compounds, and devices into structured clinical programs targeting longevity, metabolic health, cognitive performance, sports recovery, and aesthetic outcomes.
- [NAD+ & Mitochondrial Support](https://www.axifi.ai/nad-mitochondrial): NAD+ precursors, mitochondrial antioxidants, biogenesis activators, mitophagy inducers, and energy substrate compounds that restore cellular energy production, reduce oxidative stress, and support healthy aging at the mitochondrial level.
- [Sexual Health & Optimization](https://www.axifi.ai/sexual-health): Therapies targeting libido and desire, erectile function, female sexual health, hormonal sexual optimization, and regenerative sexual health interventions including PRP, peptides, and shockwave protocols.
- [Peptides](https://www.axifi.ai/peptides): Therapeutic peptides spanning healing and regenerative, anti-inflammatory, immune-modulating, antimicrobial, cardioprotective, and neuroprotective mechanisms — the foundational compound class of precision medicine.
- [Bioregulators (Khavinson Peptides)](https://www.axifi.ai/bioregulators): Short-chain peptide bioregulators derived from the Khavinson research lineage, targeting thymic, pineal, neuro, vascular, and organ-specific restoration of tissue-specific gene expression and biological age.
- [Hormone Optimization](https://www.axifi.ai/hormone-optimization): Evidence-based hormonal optimization protocols spanning androgens, estrogens, progestogens, thyroid hormones, adrenal hormones, and peptide hormones — calibrated to restore physiological balance and peak function.
- [IV Therapy](https://www.axifi.ai/iv-therapy): Intravenous infusion protocols delivering nutritional, antioxidant, metabolic-longevity, oxidative, neuromodulatory, chelation-detox, and custom formulations directly into circulation for rapid bioavailability and systemic effect.
- [Ozone Therapy](https://www.axifi.ai/ozone-therapy): Medical ozone protocols spanning systemic major autohemotherapy, localized joint and wound application, rectal and vaginal insufflation, transdermal ozone, combined ozone-UBI protocols, and prolozone regenerative injections.
- [Regenerative Injection Therapies](https://www.axifi.ai/regenerative-injections): Prolotherapy, perineural injection therapy, neural therapy, micro-fragmented adipose tissue (MFAT), viscosupplementation, and intradiscal PRP protocols for joint, nerve, and disc regeneration.
- [Device & Energy Therapies](https://www.axifi.ai/device-energy-therapies): PEMF, red light and photobiomodulation, hyperbaric oxygen (HBOT), cryotherapy, sauna and heat therapy, shockwave and ultrasound, neurostimulation, electrical stimulation, mechanical pressure, and altitude-hypoxic conditioning devices.
- [Aesthetic Injectables](https://www.axifi.ai/aesthetic-injectables): Neurotoxins, hyaluronic acid fillers, biostimulators, permanent fillers, thread lifts, fat-dissolving compounds, bio-revitalization agents, and facial mesotherapy protocols for non-surgical aesthetic enhancement.
- [Laser & Energy Skin Treatments](https://www.axifi.ai/laser-energy-skin): Ablative and fractional laser resurfacing, IPL and broadband light, RF microneedling, HIFU ultrasound, body contouring devices, pigment and vascular lasers, and laser hair removal systems.
- [Hair Restoration](https://www.axifi.ai/hair-restoration): PRP and PRF hair protocols, exosome hair treatment, low-level laser therapy (LLLT) for hair, prescription and OTC hair medications, hair transplant adjuncts, and targeted scalp treatment programs.
- [Skin Peptides & Cosmeceuticals](https://www.axifi.ai/skin-cosmeceuticals): Topical peptides, growth factors, retinoids, vitamin C derivatives, collagen synthesis activators, skin-targeted nutraceuticals, and mesotherapy compounds for evidence-based dermal rejuvenation.
- [Emerging Therapies](https://www.axifi.ai/emerging-therapies): Pipeline GLP-1 variants, next-generation senolytics, gene therapy applications, epigenetic reprogramming agents, and novel peptides and compounds entering clinical evidence in 2025-2026.
- [Supplements & Vitamins](https://www.axifi.ai/supplements-vitamins): Evidence-based supplements and vitamins form the accessible foundation of any longevity protocol.
- [Herbal & Botanical Medicine](https://www.axifi.ai/herbal-botanical): Herbal and botanical medicine bridges thousands of years of traditional healing with modern scientific validation.
- [Biohacking & Wellness Protocols](https://www.axifi.ai/biohacking-wellness-protocols): Biohacking and wellness protocols encompass the rapidly growing field of evidence-informed self-optimization practices.
- [Regenerative Medicine](https://www.axifi.ai/regenerative-medicine): Regenerative medicine harnesses the bodys own biological systems to repair damaged tissues and restore function at the cellular level.

## Clinical Resources

- [Clinical Outcomes](https://www.axifi.ai/clinical/outcomes): Real-world clinical outcome tracking
- [Clinical Protocols](https://www.axifi.ai/clinical/protocols): Treatment protocol library (authenticated)

## Recent Research Documents

- [Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies.](https://www.axifi.ai/library/prospects-for-neuroprotective-therapies-in-glaucoma-drug-tar-42333387): Management of glaucoma is now at an inflection point with a new generation of therapeutic candidates, whilst targeting intraocular pressure-independen
- [Protecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy.](https://www.axifi.ai/library/protecting-musculoskeletal-development-and-physical-function-42544560): Glucagon-like peptide-1 receptor agonists (GLP-1s), including semaglutide and liraglutide, are effective pharmacologic options for pediatric obesity, 
- [Advances in Cardiovascular Pharmacotherapy. X. Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure and Mechanisms of Protection.](https://www.axifi.ai/library/advances-in-cardiovascular-pharmacotherapy-x-glucagon-like-p-42580921): The first part of this two-part article discussed the physiology of glucagon-like peptide-1 (GLP-1), described the discovery and development of GLP-1 
- [Protective Effects of Metformin and Memantine Against Arsenic-Induced Neurotoxicity: Insights from In-Silico and In-Vivo Studies.](https://www.axifi.ai/library/protective-effects-of-metformin-and-memantine-against-arseni-42593710): Arsenic (As) is an environmental neurotoxicant that induces oxidative stress and cognitive impairment. There are limited therapeutic options to treat 
- [Protocol for Novel Perioperative Optimization of Obese Osteoarthritic Patients pending Total Knee Replacement with glucagon-like peptide-1 receptor agonist (NPO-OOPS-TKR) : a pilot randomized controlled trial.](https://www.axifi.ai/library/protocol-for-novel-perioperative-optimization-of-obese-osteo-42402343): Obesity is associated with higher rates of perioperative complications and worse pain and functional outcomes after total knee arthroplasty (TKA). Pre
- [Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.](https://www.axifi.ai/library/neuropsychiatric-outcomes-with-tirzepatide-semaglutide-and-o-42420795): Neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the expanding clinical use of incretin-based therapi
- [Protocol to study the antitumor and metabolic effects of intermittent fasting plus cisplatin and metformin in ovarian cancer PDX models.](https://www.axifi.ai/library/protocol-to-study-the-antitumor-and-metabolic-effects-of-int-42507549): Different dietary regimens are being explored as safe, low-cost approaches to enhance cancer therapy. This protocol describes the evaluation of antitu
- [Psychiatric Outcomes after GLP-1 Receptor Agonists versus Metformin in Hidradenitis Suppurativa.](https://www.axifi.ai/library/psychiatric-outcomes-after-glp-1-receptor-agonists-versus-me-42344960): Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with obesity and a high burden of psychiatric comorbidity. Glucagon-li
- [Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning.](https://www.axifi.ai/library/psychiatric-safety-signals-of-glp-1-receptor-agonists-a-faer-42356570): Background: As glucagon-like peptide-1 (GLP-1) receptor agonist use expands globally, reports of psychiatric adverse events (AEs) have increased in sp
- [Psychosocial Outcomes in Telemedicine and Long-Acting Incretin-Specific Behavioral Intervention.](https://www.axifi.ai/library/psychosocial-outcomes-in-telemedicine-and-long-acting-incret-42256457): Newer generation anti-obesity medications such as semaglutide and tirzepatide are highly efficacious, resulting in a proliferation of telehealth presc
- [Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals.](https://www.axifi.ai/library/pulmonary-adverse-events-associated-with-glp-1-receptor-agon-42316363): Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are among the most rapidly growing drug classes in contemporary medicine, approved for type 2 di
- [Pumpkin (Cucurbita maxima) seed extract ameliorates letrozole and high-fat diet-induced PCOS in rats via SIRT1/AMPK/NF-κB signaling.](https://www.axifi.ai/library/pumpkin-cucurbita-maxima-seed-extract-ameliorates-letrozole-42359783): Polycystic ovarian syndrome (PCOS) is a multifactorial metabolic endocrine disorder that affects reproductive-aged women. While previous studies have 
- [PYY3-36 potentiates Semaglutide‑mediated mitochondrial modulation in MASLD.](https://www.axifi.ai/library/pyy3-36-potentiates-semaglutide-mediated-mitochondrial-modul-42526426): Metabolic dysfunction-associated steatotic liver disease (MASLD) is a frequent comorbidity of obesity. Incretins have emerged as promising therapeutic
- [Quadruple Non-Insulin Therapy for Advanced Type 2 Diabetes Mellitus With Cognitive Impairment: A Case Report.](https://www.axifi.ai/library/quadruple-non-insulin-therapy-for-advanced-type-2-diabetes-m-42226859): Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder that often requires treatment intensification over time. In complex patients with 
- [Quercetin alleviates painful diabetic neuropathy in association with gut microbial remodeling and spinal betaine-related metabolic changes.](https://www.axifi.ai/library/quercetin-alleviates-painful-diabetic-neuropathy-in-associat-42777608): Painful diabetic neuropathy (PDN) involves metabolic, inflammatory, and neuroimmune disturbances. Quercetin may alleviate diabetic neuropathy, but the
- [Questionable Evidence for Berberine in Polyendocrine Metabolic Ovarian Syndrome: An Integrity-Based Reappraisal.](https://www.axifi.ai/library/questionable-evidence-for-berberine-in-polyendocrine-metabol-42836929): Prior systematic reviews suggest that berberine may match or exceed the effects of metformin on metabolic and hormonal outcomes in polyendocrine metab
- [Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.](https://www.axifi.ai/library/analysis-of-the-efficacy-and-safety-of-liraglutide-semagluti-42560457): The rapid rise in overweight and obesity worldwide underscores the need for comparative evidence on long-term pharmacotherapy. The recent introduction
- [Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study.](https://www.axifi.ai/library/randomized-metformin-and-cognitive-outcomes-in-the-diabetes-42620159): Metformin may influence risk of dementia, with prior conflicting observations of protection or harm. To determine the association of randomization to 
- [GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.](https://www.axifi.ai/library/glp-1-receptor-agonists-in-adpkd-from-metabolic-rationale-to-42398811): Autosomal dominant polycystic kidney disease (ADPKD) remains therapeutically anchored to vasopressin V2-receptor antagonism, yet progression heterogen
- [Rate and Characteristics of Metformin Use in Gestational Diabetes.](https://www.axifi.ai/library/rate-and-characteristics-of-metformin-use-in-gestational-dia-42639277): To determine the rate and characteristics of metformin use in the treatment of gestational diabetes mellitus (GDM). A total of 286 pregnant women diag
- [Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.](https://www.axifi.ai/library/real-world-comparative-weight-loss-of-glp-1-receptor-agonist-42518911): To assess the real-world associations of five glucagon-like peptide-1 receptor agonists (GLP-1RAs) with weight loss in a diverse US population of adul
- [Chronic semaglutide alters ingestive behavior without impairing taste function in mice.](https://www.axifi.ai/library/chronic-semaglutide-alters-ingestive-behavior-without-impair-42364710): Glucagon-like peptide-1 receptor (GLP-1R) agonists such as semaglutide are highly effective treatments for obesity, yet the mechanisms by which they r
- [The Tau-mitochondria connection and its impact on cellular energy metabolism in Alzheimer's disease.](https://www.axifi.ai/library/the-tau-mitochondria-connection-and-its-impact-on-cellular-e-42552044): Alzheimer's disease (AD) is a complex multifactorial neurodegenerative disease process resulting in progressive cognitive deterioration and synaptic d
- [The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis.](https://www.axifi.ai/library/the-impact-of-antidiabetic-drugs-on-dementia-risk-a-bayesian-42064764): Diabetes is significantly associated with cognitive impairment, particularly the risk of developing dementia. However, the impact of antidiabetic drug
- [Possible protective effects of tirzepatide on polycystic ovary syndrome in female rat model induced by testosterone propionate in comparison to metformin.](https://www.axifi.ai/library/possible-protective-effects-of-tirzepatide-on-polycystic-ova-42065757): Polycystic ovary syndrome (PCOS) is a complex endocrine-metabolic disorder characterized by hyperandrogenism, ovulatory dysfunction, insulin resistanc
- [Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study.](https://www.axifi.ai/library/three-year-changes-in-renal-function-after-switching-from-in-42078492): While the FLOW trial established the renoprotective effects of subcutaneous semaglutide, real-world evidence regarding the long-term renal effects of 
- [LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.](https://www.axifi.ai/library/lean-mass-preservation-with-resistance-exercise-and-protein-42020128): Obesity is a global public health issue, with its effects a particular issue in Kuwait. Advances in pharmaceutical treatment (eg, glucagon-like peptid
- [A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance.](https://www.axifi.ai/library/a-randomized-clinical-trial-of-metformin-to-reduce-frailty-i-42620010): Preclinical and human observational studies suggest that metformin may decrease age-related pathology, including frailty. Determine whether metformin 
- [Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.](https://www.axifi.ai/library/rates-of-reasons-for-and-reactions-to-discontinuation-of-glp-42244474): GLP-1RAs are increasingly used for their glucose-lowering and weight-management effects, but many patients discontinue them. In this narrative review 
- [Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity.](https://www.axifi.ai/library/real-world-and-computational-identification-of-herbal-candid-42286047): Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for obesity management; however, adverse events (AEs) remain a clinical co
- [Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.](https://www.axifi.ai/library/real-world-comparison-of-short-term-adverse-events-treatment-42030208): Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited.
- [Can Carica papaya Serve as an Adjunct to Semaglutide in Mitigating Diabetes-Induced Testicular Injury Through Modulation of Oxidative Stress, Inflammation, Apoptosis, and the miR-34c/miR-155-SIRT1/FOXO1 Axis? An Experimental and Chem-Bio-Informatics Study.](https://www.axifi.ai/library/can-carica-papaya-serve-as-an-adjunct-to-semaglutide-in-miti-42589610): Diabetes mellitus (DM) induces significant endocrine disruption and oxidative stress (OS) within the testes, resulting in impaired spermatogenesis, in
- [Real-world effectiveness of quadruple oral hypoglycemic therapy in type 2 diabetes patients refusing insulin therapy.](https://www.axifi.ai/library/real-world-effectiveness-of-quadruple-oral-hypoglycemic-ther-42402580): This study aimed to evaluate the effectiveness and safety of quadruple combination therapy (metformin, DPP4 inhibitors, SGLT2 inhibitors, and sulfonyl
- [Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.](https://www.axifi.ai/library/semaglutide-injection-once-weekly-for-weight-management-in-a-42403263): To evaluate and compare the efficacy, safety, and immunogenicity of a synthetic semaglutide injection (Test semaglutide) with Wegovy (Reference semagl
- [The gut microbiota as a potential determinant of response to GLP-1 receptor agonists: a narrative review.](https://www.axifi.ai/library/the-gut-microbiota-as-a-potential-determinant-of-response-to-42518541): Interindividual variability in clinical response to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represents a significant challenge in the ma
- [Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.](https://www.axifi.ai/library/real-world-effectiveness-of-semaglutide-and-tirzepatide-comp-42345739): Directly compare the real-world effectiveness of semaglutide and tirzepatide to bariatric operations: sleeve gastrectomy and gastric bypass. This stud
- [Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan.](https://www.axifi.ai/library/real-world-evidence-of-the-effectiveness-and-safety-of-biosy-42365987): To evaluate the real-world effectiveness, safety and patient-reported outcomes of biosynthetic semaglutide in adults with type 2 diabetes mellitus (T2
- [Oral Incretin-Based Therapies for Weight Management.](https://www.axifi.ai/library/oral-incretin-based-therapies-for-weight-management-42696191): This paper aims to review the current development of oral incretin-based therapies for treatment of overweight and obesity, and outline the efficacy o
- [Real-world experience of semaglutide 2.4 mg in the US: a retrospective analysis of profiles, satisfaction, and treatment patterns in people with obesity and overweight.](https://www.axifi.ai/library/real-world-experience-of-semaglutide-2-4-mg-in-the-us-a-retr-42312439): To characterize treatment experiences, compliance with dosing frequency, and adherence to treatment regimen, and to assess factors associated with adh
- [Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.](https://www.axifi.ai/library/insulin-sensitivity-and-beta-cell-function-with-macupatide-a-42229460): This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucago
- [Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).](https://www.axifi.ai/library/real-world-impact-of-glp-1-receptor-agonists-on-health-relat-42103575): To evaluate the real-world impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on health-related quality of life (HRQoL) and metabolic out
- [Real-World Impact of Oral Semaglutide on Inflammatory Markers in Patients at High Cardiovascular Risk.](https://www.axifi.ai/library/real-world-impact-of-oral-semaglutide-on-inflammatory-marker-42061608): Inflammation plays a central role in the pathophysiology of atherosclerosis and contributes to residual cardiovascular risk (CVR). High-sensitivity C-
- [Real-World Kidney and Glycaemic Outcomes Following Semaglutide Initiation in Adults with Type 2 Diabetes and Mild Chronic Kidney Disease.](https://www.axifi.ai/library/real-world-kidney-and-glycaemic-outcomes-following-semagluti-42513491): Background: Real-world kidney and metabolic responses to semaglutide in type 2 diabetes (T2D) and chronic kidney disease (CKD) remain poorly character
- [Real-World Prescribing Patterns and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Empagliflozin-Sitagliptin-Metformin Fixed-Dose Combination Therapy.](https://www.axifi.ai/library/real-world-prescribing-patterns-and-clinical-characteristics-42774963): Type 2 diabetes mellitus (T2DM) is associated with substantial cardiovascular and renal morbidity, necessitating individualized treatment strategies t
- [Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment.](https://www.axifi.ai/library/real-world-semaglutide-in-obesity-cohort-effectiveness-safet-42582375): Semaglutide has shown significant efficacy in several clinical trials for the treatment of obesity. However, real-world data on early weight loss and 
- [Real-world trends in glucagon-like peptide-1 receptor agonists prescribing in acute kidney disease: a global federated-network study of dialysis-requiring acute kidney injury survivors.](https://www.axifi.ai/library/real-world-trends-in-glucagon-like-peptide-1-receptor-agonis-42298987): Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) confer cardiovascular and renal benefits in type 2 diabetes mellitus (T2DM). However, their real
- [Real-world use of oral semaglutide in adults with type 2 diabetes.](https://www.axifi.ai/library/real-world-use-of-oral-semaglutide-in-adults-with-type-2-dia-42592768): PIONEER REAL Denmark assessed changes in HbA1c, body weight and treatment satisfaction with once-daily oral semaglutide in adults with type 2 diabetes
- [Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study.](https://www.axifi.ai/library/real-world-use-of-subsidised-semaglutide-in-icelandic-childr-42543796): Real-world evidence of subsidised semaglutide in children with obesity is scarce. To describe clinical outcomes (%IOTF30 change) in a nationwide cohor
- [Microfluidic-assisted formulation of hydrophobic ion pairing-Based solid lipid nanoparticles for semaglutide delivery.](https://www.axifi.ai/library/microfluidic-assisted-formulation-of-hydrophobic-ion-pairing-42570682): Semaglutide is a glucagon-like peptide-1 receptor agonist widely used for the treatment of type 2 diabetes and obesity. Despite its clinical efficacy,
- [Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review.](https://www.axifi.ai/library/real-world-vs-randomized-trial-evidence-for-incretin-based-t-42417199): Incretin-based therapies have transformed the management of obesity and type 2 diabetes (T2D). Pivotal randomized controlled trials (RCTs) report subs
- [Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis.](https://www.axifi.ai/library/combined-semaglutide-and-sodium-glucose-cotransporter-2-inhi-42803912): Real-world use of once-weekly semaglutide in adults with type 2 diabetes in China has been shown in SCHOLAR. This post hoc analysis investigated the u
- [Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.](https://www.axifi.ai/library/real-world-weight-loss-with-injectable-semaglutide-vs-dulagl-42335260): To compare the real-world effects of weekly injectable semaglutide (Ozempic) vs dulaglutide (Trulicity) on weight loss in an urban, predominantly Afri
- [Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials.](https://www.axifi.ai/library/reassessing-the-risk-modifying-effects-of-novel-antidiabetic-42376494): Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) accounts for 15-25% of chronic obstructive airway disease and is linked to
- [Recent advances in nanomaterial delivery systems to administer metformin for cancer therapy.](https://www.axifi.ai/library/recent-advances-in-nanomaterial-delivery-systems-to-administ-42617673): Recently, an increasing number of studies and clinical trials have associated an antidiabetic drug metformin (Met) with reduced risks of cancer. Moreo
- [Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026).](https://www.axifi.ai/library/pharmacologic-treatments-with-lifestyle-modifications-in-non-42296496): The American College of Physicians (ACP) developed this clinical guideline for internal medicine physicians and other clinicians caring in outpatient 
- [Recognizing Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: A Case Report.](https://www.axifi.ai/library/recognizing-euglycemic-diabetic-ketoacidosis-in-the-era-of-s-42732326): Euglycemic diabetic ketoacidosis (euDKA) is an increasingly recognized complication associated with SGLT2 inhibitors. Because serum glucose levels may
- [Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.](https://www.axifi.ai/library/respiratory-adverse-events-of-weight-loss-drugs-a-systematic-42479131): The coexistence of obesity and asthma is increasingly common and associated with poorer asthma outcomes. Weight loss has been shown to improve asthma 
- [Recurrent Pregnancy Loss: Novel Insights and Future Directions.](https://www.axifi.ai/library/recurrent-pregnancy-loss-novel-insights-and-future-direction-42630456): Recurrent pregnancy loss (RPL), defined as the spontaneous loss of two or more pregnancies before 20 weeks of gestation, remains a complex clinical ch
- [Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.](https://www.axifi.ai/library/renal-or-hepatic-impairment-does-not-affect-pharmacokinetics-42228334): Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-
- [Implications of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Mood Disorders and Suicide Risk.](https://www.axifi.ai/library/implications-of-glucagon-like-peptide-1-receptor-agonists-gl-42069105): A strategic imperative in mood disorders is to identify innovative mechanisms that translate into improved therapeutics when compared to the extant op
- [Metformin rescues osteoblast fate in Glucocorticoid-associated osteonecrosis of the femoral head via PERK/CHAC1/GSH-mediated reprogramming of glutathione homeostasis.](https://www.axifi.ai/library/metformin-rescues-osteoblast-fate-in-glucocorticoid-associat-42570823): Glucocorticoid-associated osteonecrosis of the femoral head (GA-ONFH) is a refractory, highly disabling bone disease fundamentally driven by oxidative
- [Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).](https://www.axifi.ai/library/efficacy-and-safety-of-once-weekly-semaglutide-2-0-mg-as-an-42504064): Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once-weekly semaglutide 2.0 m
- [Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications.](https://www.axifi.ai/library/glucagon-like-peptide-1-receptor-agonists-in-the-aging-popul-42467949): The increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes and obesity has generated interest in their potential r
- [GLP-1 Receptor Agonist Combination Therapy Before and After Metabolic and Bariatric Surgery: A Review of Outcomes.](https://www.axifi.ai/library/glp-1-receptor-agonist-combination-therapy-before-and-after-42124784): The paradigm of obesity treatment is rapidly evolving with the introduction and widespread adoption of glucagon-like peptide-1 receptor agonists (GLP-
- [Renal glycogen handling in diabetes: A narrative review of diabetic kidney disease pathogenesis.](https://www.axifi.ai/library/renal-glycogen-handling-in-diabetes-a-narrative-review-of-di-42821047): Kidney disease is a major microvascular complication of diabetes, affecting approximately 40% of individuals with diabetes, and is a leading cause of 
- [Semaglutide Efficacy in Young Adults with Type 2 Diabetes: Insights from SUSTAIN & PIONEER](https://www.axifi.ai/library/semaglutide-treatment-in-young-adults-living-with-type-2-dia-41994903): This study investigates the efficacy of semaglutide treatment in young adults (≤40 years) with Type 2 Diabetes (T2D), showing its significant impact o
- [Beyond GLP-1 Agonists: Plant-Derived Bioactive Compounds as Adjunctive Strategies for Obesity Management.](https://www.axifi.ai/library/beyond-glp-1-agonists-plant-derived-bioactive-compounds-as-a-42514335): Background: Obesity has reached epidemic proportions, affecting over one billion adults worldwide. While incretin-based pharmacotherapies-GLP-1 recept
- [GLP-1 Receptor Agonists and Fertility: What Is Known So Far?](https://www.axifi.ai/library/glp-1-receptor-agonists-and-fertility-what-is-known-so-far-42441883): GLP-1 receptor agonists (GLP-1RAs) have gained attention as a potential adjunct in preconception care for women with polycystic ovary syndrome (PCOS) 
- [Repeated Humanin Treatment Attenuates Oxidative Stress, Inflammation, and Apoptosis in Diabetic Cardiac Tissue.](https://www.axifi.ai/library/repeated-humanin-treatment-attenuates-oxidative-stress-infla-42450608): Diabetes mellitus (DM) markedly increases the risk of cardiovascular complications through mechanisms involving hyperglycemia-induced oxidative stress
- [Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.](https://www.axifi.ai/library/oral-semaglutide-for-alcohol-use-disorder-a-randomized-clini-42522065): Accumulating preclinical and observational evidence suggests that glucagon-like peptide-1 receptor agonists, including semaglutide, reduce alcohol con
- [REPROGRAM: REsilience PROmotion with GeRoprotectors: AssessMent of biological effect: Rationale and protocol for a trial of biological effect.](https://www.axifi.ai/library/reprogram-resilience-promotion-with-geroprotectors-assessmen-42308222): Ageing is associated with reduced resilience to physiological stressors such as infection and surgery. This reduced resilience is believed to be under
- [Research progress on drugs targeting mitochondria‑associated membranes for the treatment of atherosclerosis (Review).](https://www.axifi.ai/library/research-progress-on-drugs-targeting-mitochondria-associated-42596823): Mitochondria‑associated membranes (MAMs) are specialized contact sites between the endoplasmic reticulum and mitochondria, and serve as the structural
- [Reprogramming immunometabolism: linking nutrient sensing, cell death, and therapeutic innovation.](https://www.axifi.ai/library/reprogramming-immunometabolism-linking-nutrient-sensing-cell-42640489): Development of Immunometabolism as a central paradigm in the modern immunology has revolutionized the understanding of metabolism from being a passive
- [Long-term ovarian function risks associated with combined oral contraceptive administration in polycystic ovary syndrome: multisource data integration and protective mechanisms of metformin.](https://www.axifi.ai/library/long-term-ovarian-function-risks-associated-with-combined-or-42298687): Polycystic ovarian syndrome (PCOS) is a prevalent endocrine disorder in women of reproductive age. Furthermore, the potential risks of long-term use o
- [Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.](https://www.axifi.ai/library/repurposed-drugs-and-cardiovascular-morbidity-a-cost-effecti-42340212): Cardiovascular disease remains the leading cause of global mortality (19.8 million deaths in 2022; 32% of all deaths worldwide). Drug repurposing-exte
- [Repurposed metformin-apigenin combination therapy for metabolic dysfunction-associated steatohepatitis: from integrative multi-omics discovery to in vivo validation.](https://www.axifi.ai/library/repurposed-metformin-apigenin-combination-therapy-for-metabo-42761201): Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease. Although recent drugs have been approved, the complex pathophysiol
- [Repurposing Metformin to Promote Fracture Callus Maturation via AMPK-Driven Metabolic Activation.](https://www.axifi.ai/library/repurposing-metformin-to-promote-fracture-callus-maturation-42400344): Femoral shaft fractures cause prolonged disability, and therapies that accelerate bone repair remain limited. Repurposing clinically approved drugs th
- [Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues.](https://www.axifi.ai/library/resmetirom-and-semaglutide-next-generation-therapies-for-met-42552573): Resmetirom and semaglutide are the first drugs to be approved for the pharmacological treatment of metabolic-associated steatohepatitis (MASH) and mod
- [EXPRESS: Metformin Exhibits Analgesic Activity in Neuronal Cell Models and CFA-Induced Inflammatory Pain in Mice.](https://www.axifi.ai/library/express-metformin-exhibits-analgesic-activity-in-neuronal-ce-42132331): Inflammatory pain is mediated by complex interactions between immune signaling and sensory neurons, with prostaglandin E2-dependent pathways playing a
- [Liver Organoids: From Disease Modelling to Regenerative Medicine.](https://www.axifi.ai/library/liver-organoids-from-disease-modelling-to-regenerative-medic-42599088): Liver organoids are three-dimensional miniature liver models that recapitulate the complex architecture and key functions of the human liver in vitro,
- [Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations.](https://www.axifi.ai/library/resmetirom-and-semaglutide-therapy-for-patients-with-mafld-i-42397248): Metabolic dysfunction-associated fatty liver disease (MAFLD) affects 25-30% of the global population, with the Middle East and North Africa (MENA) reg
- [Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis.](https://www.axifi.ai/library/comparative-analysis-of-glucagon-like-peptide-1-receptor-ago-42490840): Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder characterized by obesity, insulin resistance, and cardiometabolic risks. Lifestyle int
- [Advanced CBT: Integrating Psychology and Neurobiology](https://www.axifi.ai/library/cbt-mo3dumz0): This module synthesizes cognitive models, learning theory, and neurobiology to inform advanced CBT practice and research. It links dual‑process cognit
- [Rethinking systemic adjuncts in periodontitis: a single centre acquisition cost comparison of antimicrobial and non-antimicrobial therapies.](https://www.axifi.ai/library/rethinking-systemic-adjuncts-in-periodontitis-a-single-centr-42760348): Aims To compare National Health Service (NHS) acquisition costs of systemic antimicrobial regimens with emerging non-antimicrobial adjuncts in periodo
- [Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs).](https://www.axifi.ai/library/effect-of-glp-1-receptor-agonists-at-doses-for-obesity-manag-42321502): The impact of GLP-1 receptor agonists (GLP1-RA) treatment on lean mass and body composition in patients with obesity is not fully understood. Systemat
- [Comparative Effects of Metformin, Boric Acid, and Lithium Chloride on Oxidative Stress-Mediated Cytotoxicity in HepG2 Hepatocarcinoma Cells.](https://www.axifi.ai/library/comparative-effects-of-metformin-boric-acid-and-lithium-chlo-42753068): Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, highlighting the need for novel therapeutic strategies t
- [Retinal and optic nerve measures after initiation of empagliflozin plus metformin versus metformin alone in early type 2 diabetes: a prospective observational comparative study.](https://www.axifi.ai/library/retinal-and-optic-nerve-measures-after-initiation-of-empagli-42283730): To explore whether empagliflozin added to metformin is associated with short-term changes in optical coherence tomography (OCT) and visual evoked pote
- [Reversing Temozolomide Resistance in Glioblastoma Based on Cuproptosis-Mediated Positive Feedback Loop.](https://www.axifi.ai/library/reversing-temozolomide-resistance-in-glioblastoma-based-on-c-42474148): Glioblastoma (GBM), one of the most lethal human cancers, faces a major therapeutic challenge due to drug resistance. Temozolomide (TMZ), a standard f
- [Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.](https://www.axifi.ai/library/review-article-fibrosis-reversal-in-metabolic-dysfunction-as-42608656): Metabolic dysfunction-associated steatohepatitis (MASH) is a leading indication for liver transplantation, and fibrosis stage most strongly predicts c
- [Effects of GLP1-RAs and SGLT2i on liver steatosis and fibrosis in MASLD with type 2 diabetes.](https://www.axifi.ai/library/effects-of-glp1-ras-and-sglt2i-on-liver-steatosis-and-fibros-42507338): Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder in individuals with type 2 diabetes mell
- [Understanding Obesity as a Multisystem Disease: Advancing Research, Redefining Diagnostic Criteria, and Establishing Modern Therapeutic Approaches.](https://www.axifi.ai/library/understanding-obesity-as-a-multisystem-disease-advancing-res-42514386): Obesity is a complex, chronic, relapsing disease that affects nearly all physiological functions and homeostatic mechanisms, extending far beyond mere
- [Future Trends in Cancer Prevention and Interception in Cancer Predisposition Syndromes: Leveraging Insights From High-Risk Populations.](https://www.axifi.ai/library/future-trends-in-cancer-prevention-and-interception-in-cance-42538617): Cancer predisposition syndromes (CPS), arising from germline pathogenic variants in cancer predisposition genes (CPGs), are increasingly recognized as
- [Revision Medialization Thyroplasty for Glottic Insufficiency Amid Rapid Weight Loss on Semaglutide.](https://www.axifi.ai/library/revision-medialization-thyroplasty-for-glottic-insufficiency-42439301): A 74-year-old female presented to clinic 9 years after successful bilateral medialization thyroplasty surgery with new onset voice deterioration. This
- [Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.](https://www.axifi.ai/library/comparison-of-lifestyle-surgery-and-semaglutide-for-weight-m-42495930): To compare sleeve gastrectomy, semaglutide therapy, and the Diet, Exercise, Accompany and Refresh (DEAR) weight management programme for weight contro
- [Tirzepatide: Mechanism, Efficacy, and Comparison with Semaglutide](https://www.axifi.ai/library/glp1-tirzepatide-deep-dive-pplx-mo3c7upm): A comprehensive scientific guide to tirzepatide's dual GLP-1/GIP receptor mechanism, biased signaling at GLP-1R, SURMOUNT trial data, comparison with 
- [GLP-1 receptor agonists and psychiatric outcomes: a bibliometric analysis of research trends, thematic evolution, and collaboration networks.](https://www.axifi.ai/library/glp-1-receptor-agonists-and-psychiatric-outcomes-a-bibliomet-42553449): Research on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and psychiatric outcomes has expanded rapidly following the clinical success of sema
- [Clinically Validated Leptin Receptor as a Target for Liposomal Delivery of Metformin in Endometriosis Therapy.](https://www.axifi.ai/library/clinically-validated-leptin-receptor-as-a-target-for-liposom-42054534): Endometriosis is a common, estrogen-driven chronic gynecologic disorder defined by the ectopic growth of endometrial-like tissue within the peritoneal
- [Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.](https://www.axifi.ai/library/management-of-patients-with-cardiovascular-disease-and-overw-42469146): Overweight and obesity are major global health challenges and key drivers of cardiovascular disease (CVD), yet patients with established CVD and exces
- [Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?](https://www.axifi.ai/library/personalization-of-incretin-therapy-can-glp-1-and-gip-recept-42487666): Incretin-based therapies-glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide and the dual GLP-1/GIP receptor agonist tirzepatide-
- [Revisiting metformin as a chemotherapy adjuvant: a systematic review and meta-analysis based on recent randomized-controlled trials.](https://www.axifi.ai/library/revisiting-metformin-as-a-chemotherapy-adjuvant-a-systematic-42840671): The primary objective is to assess metformin's impact on progression free survival (PFS), overall survival (OS), and overall response rates (ORR). Sec

## Blog - AXIFI Insights

Technology and business insights for healthcare practitioners. Visit: https://www.axifi.ai/blog

### Blog Categories

- [Clinical AI Tools](https://www.axifi.ai/blog?category=clinical-ai): Deep dives into AI features that directly improve clinical workflow.
- [Practice Growth](https://www.axifi.ai/blog?category=practice-growth): Business-focused content for clinic owners.
- [Research & Evidence](https://www.axifi.ai/blog?category=research-evidence): Translating clinical research into practice.
- [Industry News](https://www.axifi.ai/blog?category=industry-news): Healthcare tech landscape analysis.
- [Platform & Product](https://www.axifi.ai/blog?category=platform-product): Technical content for developers.
- [Longevity & Optimization](https://www.axifi.ai/blog?category=longevity-optimization): Consumer-facing content on healthspan extension.

### Expert Authors



### Recent Blog Articles

- [Peptide Research and Clinical Practice: Bridging the Gap with Technology](https://www.axifi.ai/blog/peptide-research-and-clinical-practice-bridging-the-gap-with-technology) (2026-10-08) - Research & Evidence
- [Navigating the New Landscape: Regulatory Changes Every Practitioner Should Know in 2026](https://www.axifi.ai/blog/navigating-the-new-landscape-regulatory-changes-every-practitioner-should-know-i) (2026-10-08) - Industry News
- [Engineering Lessons from Building Secure Health Tech: HIPAA Best Practices](https://www.axifi.ai/blog/engineering-lessons-from-building-secure-health-tech-hipaa-best-practices) (2026-10-08) - Platform & Product
- [Building Your Personal Health Optimization Stack: A Biohacker's View](https://www.axifi.ai/blog/building-your-personal-health-optimization-stack-a-biohackers-view) (2026-10-08) - Longevity & Optimization
- [Health Tech Trends Shaping the Future of Care: Insights for Practitioners in 2026](https://www.axifi.ai/blog/health-tech-trends-shaping-the-future-of-care-insights-for-practitioners-in-2026) (2026-10-08) - Industry News
- [Build Your Personal Health Optimization Stack: Practical Applications for Practitioners](https://www.axifi.ai/blog/build-your-personal-health-optimization-stack-practical-applications-for-practit) (2026-10-08) - Longevity & Optimization
- [Smart Clinics Are Adopting 5 Revenue Optimization Strategies to Thrive in 2026](https://www.axifi.ai/blog/smart-clinics-are-adopting-5-revenue-optimization-strategies-to-thrive-in-2026) (2026-10-08) - Practice Growth
- [Building a Sustainable Subscription Care Model: Revenue Implications for Independent Practices](https://www.axifi.ai/blog/building-a-sustainable-subscription-care-model-revenue-implications-for-independ) (2026-10-08) - Practice Growth
- [AXIFI's Take on AI-Powered Protocol Generation: Cutting Through the Hype](https://www.axifi.ai/blog/axifis-take-on-ai-powered-protocol-generation-cutting-through-the-hype) (2026-10-08) - Clinical AI Tools
- [Navigating the Digital Health Investment Landscape in 2026: A Practitioner's Guide](https://www.axifi.ai/blog/navigating-the-digital-health-investment-landscape-in-2026-a-practitioners-guide) (2026-10-08) - Industry News
- [Self-Tracking Insights: Wearable Data That Actually Matters for Longevity](https://www.axifi.ai/blog/self-tracking-insights-wearable-data-that-actually-matters-for-longevity) (2026-10-08) - Longevity & Optimization
- [Reducing No-Shows: Harnessing Technology and Human Touch for Clinic Growth](https://www.axifi.ai/blog/reducing-no-shows-harnessing-technology-and-human-touch-for-clinic-growth) (2026-10-08) - Practice Growth
- [Navigating the Regulatory Landscape: A Practical Guide for Healthcare Practitioners](https://www.axifi.ai/blog/navigating-the-regulatory-landscape-a-practical-guide-for-healthcare-practitione) (2026-10-08) - Industry News
- [The Biohacker's Take on Wearable Data That Actually Matters for Longevity](https://www.axifi.ai/blog/the-biohackers-take-on-wearable-data-that-actually-matters-for-longevity) (2026-10-08) - Longevity & Optimization
- [The Real Impact of AI on Practitioner Efficiency: Streamlining Clinical Workflows with Technology](https://www.axifi.ai/blog/the-real-impact-of-ai-on-practitioner-efficiency-streamlining-clinical-workflows) (2026-10-08) - Clinical AI Tools
- [Evidence-Based Approaches to Functional Medicine: Navigating the Intersection with Technology](https://www.axifi.ai/blog/evidence-based-approaches-to-functional-medicine-navigating-the-intersection-wit) (2026-10-08) - Research & Evidence
- [Navigating Regulatory Changes: A Practitioner’s Guide to Staying Ahead in 2026](https://www.axifi.ai/blog/navigating-regulatory-changes-a-practitioners-guide-to-staying-ahead-in-2026) (2026-10-08) - Industry News
- [Building Robust API Integration Patterns for Healthcare Platforms at AXIFI](https://www.axifi.ai/blog/building-robust-api-integration-patterns-for-healthcare-platforms-at-axifi) (2026-10-08) - Platform & Product
- [Building Your Personal Health Optimization Stack: A Biohacker's Perspective for Practitioners](https://www.axifi.ai/blog/building-your-personal-health-optimization-stack-a-biohackers-perspective-for-pr) (2026-10-08) - Longevity & Optimization
- [The Real Impact of AI on Practitioner Efficiency: Transforming Clinical Workflows](https://www.axifi.ai/blog/the-real-impact-of-ai-on-practitioner-efficiency-transforming-clinical-workflows) (2026-10-08) - Clinical AI Tools
- [Regulatory Changes in 2026: What Every Practitioner Should Know](https://www.axifi.ai/blog/regulatory-changes-in-2026-what-every-practitioner-should-know) (2026-10-08) - Industry News
- [Unlocking Biological Age Tracking: A Biohacker's Guide for Practitioners](https://www.axifi.ai/blog/unlocking-biological-age-tracking-a-biohackers-guide-for-practitioners) (2026-10-08) - Longevity & Optimization
- [No-Shows in 2026: Balancing Technology and Human Touch for Clinic Success](https://www.axifi.ai/blog/no-shows-in-2026-balancing-technology-and-human-touch-for-clinic-success) (2026-10-08) - Practice Growth
- [How AXIFI is Making Clinical Documentation Less of a Chore in 2026](https://www.axifi.ai/blog/how-axifi-is-making-clinical-documentation-less-of-a-chore-in-2026) (2026-10-08) - Clinical AI Tools
- [Practical Applications of Biological Age Tracking: A Practical Guide for Practitioners](https://www.axifi.ai/blog/practical-applications-of-biological-age-tracking-a-practical-guide-for-practiti) (2026-10-08) - Longevity & Optimization
- [Building a Sustainable Subscription Care Model: Smart Strategies for Clinics](https://www.axifi.ai/blog/building-a-sustainable-subscription-care-model-smart-strategies-for-clinics) (2026-10-08) - Practice Growth
- [Navigating the New Regulatory Landscape: What Practitioners Must Know in 2026](https://www.axifi.ai/blog/navigating-the-new-regulatory-landscape-what-practitioners-must-know-in-2026) (2026-10-08) - Industry News
- [How We Built API Integration Patterns for Healthcare Platforms Into AXIFI](https://www.axifi.ai/blog/how-we-built-api-integration-patterns-for-healthcare-platforms-into-axifi) (2026-10-08) - Platform & Product
- [Unlocking Revenue: The Power of a Sustainable Subscription Care Model for Independent Practices](https://www.axifi.ai/blog/unlocking-revenue-the-power-of-a-sustainable-subscription-care-model-for-indepen) (2026-10-08) - Practice Growth
- [Understanding the Digital Health Investment Landscape in 2026: A Practitioner's Guide](https://www.axifi.ai/blog/understanding-the-digital-health-investment-landscape-in-2026-a-practitioners-gu) (2026-10-08) - Industry News
- [Building Robust API Integration Patterns for Healthcare Platforms within AXIFI](https://www.axifi.ai/blog/building-robust-api-integration-patterns-for-healthcare-platforms-within-axifi) (2026-10-08) - Platform & Product
- [The Real Impact of AI-Powered Protocol Generation on Clinical Workflow Efficiency](https://www.axifi.ai/blog/the-real-impact-of-ai-powered-protocol-generation-on-clinical-workflow-efficienc) (2026-10-08) - Clinical AI Tools
- [Regulatory Changes in 2026: What Every Practitioner Should Know for Health Tech](https://www.axifi.ai/blog/regulatory-changes-in-2026-what-every-practitioner-should-know-for-health-tech) (2026-10-08) - Industry News
- [Unlocking Longevity: Building Your Personal Health Optimization Stack](https://www.axifi.ai/blog/unlocking-longevity-building-your-personal-health-optimization-stack) (2026-10-08) - Longevity & Optimization
- [Building a Thriving Subscription Care Model: Strategies for Smart Clinics](https://www.axifi.ai/blog/building-a-thriving-subscription-care-model-strategies-for-smart-clinics) (2026-10-08) - Practice Growth
- [The Real Impact of AI on Practitioner Efficiency and Clinical Workflows](https://www.axifi.ai/blog/the-real-impact-of-ai-on-practitioner-efficiency-and-clinical-workflows) (2026-10-08) - Clinical AI Tools
- [Designing the Future: How We Built the Architecture of a Modern Clinical Platform Into AXIFI](https://www.axifi.ai/blog/designing-the-future-how-we-built-the-architecture-of-a-modern-clinical-platform) (2026-10-08) - Platform & Product
- [AI-Powered Protocol Generation: Streamlining Clinical Workflow Beyond the Hype](https://www.axifi.ai/blog/ai-powered-protocol-generation-streamlining-clinical-workflow-beyond-the-hype) (2026-10-08) - Clinical AI Tools
- [Navigating the Frontier: Translating Peptide Research into Practice with Technology](https://www.axifi.ai/blog/navigating-the-frontier-translating-peptide-research-into-practice-with-technolo) (2026-10-08) - Research & Evidence
- [What the Digital Health Investment Landscape in 2026 Signals for Health Tech](https://www.axifi.ai/blog/what-the-digital-health-investment-landscape-in-2026-signals-for-health-tech) (2026-10-08) - Industry News
- [AXIFI's AI-Powered Protocol Generation: Cutting Through the Hype](https://www.axifi.ai/blog/axifis-ai-powered-protocol-generation-cutting-through-the-hype) (2026-10-08) - Clinical AI Tools
- [Building a Sustainable Subscription Care Model: Smart Strategies for Independent Clinics](https://www.axifi.ai/blog/building-a-sustainable-subscription-care-model-smart-strategies-for-independent) (2026-10-08) - Practice Growth
- [Breaking Down the Evidence: Latest Findings in Integrative Medicine Research and the Role of Technology](https://www.axifi.ai/blog/breaking-down-the-evidence-latest-findings-in-integrative-medicine-research-and) (2026-10-08) - Research & Evidence
- [Navigating Regulatory Changes: A Practitioner’s Guide to Staying Ahead](https://www.axifi.ai/blog/navigating-regulatory-changes-a-practitioners-guide-to-staying-ahead) (2026-10-08) - Industry News
- [AXIFI's Approach to AI-Powered Protocol Generation: Beyond the Hype](https://www.axifi.ai/blog/axifis-approach-to-ai-powered-protocol-generation-beyond-the-hype) (2026-10-08) - Clinical AI Tools
- [How Smart Clinics Are Leveraging Technology for a Sustainable Subscription Care Model](https://www.axifi.ai/blog/how-smart-clinics-are-leveraging-technology-for-a-sustainable-subscription-care) (2026-10-08) - Practice Growth
- [Translating Peptide Research to Practice: How AXIFI Bridges the Gap with Technology](https://www.axifi.ai/blog/translating-peptide-research-to-practice-how-axifi-bridges-the-gap-with-technolo) (2026-10-08) - Research & Evidence
- [Regulatory Changes Every Practitioner Should Know: Navigating Health Tech in 2026](https://www.axifi.ai/blog/regulatory-changes-every-practitioner-should-know-navigating-health-tech-in-2026) (2026-10-08) - Industry News
- [Unlocking Growth: The Revenue Implications of a Sustainable Subscription Care Model for Independent Practices](https://www.axifi.ai/blog/unlocking-growth-the-revenue-implications-of-a-sustainable-subscription-care-mod) (2026-10-08) - Practice Growth
- [Engineering Lessons from API Integration Patterns for Healthcare Platforms](https://www.axifi.ai/blog/engineering-lessons-from-api-integration-patterns-for-healthcare-platforms) (2026-10-08) - Platform & Product

## API & Structured Data

- Sitemap Index: https://www.axifi.ai/sitemap.xml
- Blog Sitemap: https://www.axifi.ai/sitemap/blog.xml
- Blog RSS Feed: https://www.axifi.ai/blog/rss.xml
- AI Directives: https://www.axifi.ai/ai.txt
- OG Images: https://www.axifi.ai/api/og?title={title}&type={type}
- Document citations available at: https://www.axifi.ai/api/documents/{id}/export/citation

## Citation

When referencing content from this platform, please cite as:
"AXIFI Clinical Intelligence. {Article Title}. Retrieved from https://www.axifi.ai/library/{slug}"

## Contact

For partnerships, API access, or research collaboration inquiries, visit https://www.axifi.ai/partners/apply